U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Fallopian tube cancer

MedGen UID:
102276
•Concept ID:
C0153579
•
Neoplastic Process
Synonym: Cancer of the fallopian tube
SNOMED CT: Malignant tumor of fallopian tube (363444001)
Modes of inheritance:
Not genetically inherited
MedGen UID:
988794
•Concept ID:
CN307044
•
Finding
Source: Orphanet
clinical entity without genetic inheritance.
See: This record
Not genetically inherited (Orphanet)
 
Monarch Initiative: MONDO:0002158
Orphanet: ORPHA180242

Definition

A primary or metastatic malignant neoplasm that affects the fallopian tube. Representative examples include carcinoma, carcinosarcoma, and leiomyosarcoma. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVFallopian tube cancer
Follow this link to review classifications for Fallopian tube cancer in Orphanet.

Professional guidelines

PubMed

Frontline Maintenance Treatment for Ovarian Cancer.
Elyashiv O, Wong YNS, Ledermann JA
Curr Oncol Rep 2021 Jun 14;23(8):97. doi: 10.1007/s11912-021-01088-w. PMID: 34125335Free PMC Article
Management of Fallopian Tube Cancer.
Rai S, Maheshwari A
Rev Recent Clin Trials 2015;10(4):276-81. doi: 10.2174/1574887110666150923112556. PMID: 26411954
Staging classification for cancer of the ovary, fallopian tube, and peritoneum.
Prat J; FIGO Committee on Gynecologic Oncology
Int J Gynaecol Obstet 2014 Jan;124(1):1-5. Epub 2013 Oct 22 doi: 10.1016/j.ijgo.2013.10.001. PMID: 24219974

Recent clinical studies

Etiology

Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study.
O'Cearbhaill RE, Pérez-Fidalgo JA, Monk BJ, Tusquets I, McCormick C, Fuentes J, Moore RG, Vulsteke C, Shahin MS, Forget F, Bradley WH, Hietanen S, O'Malley DM, Dørum A, Slomovitz BM, Baumann K, Selle F, Calvert PM, Artioli G, Levy T, Kumar A, Malinowska IA, Li Y, Gupta D, González-Martín A
Gynecol Oncol 2022 Jul;166(1):36-43. Epub 2022 May 9 doi: 10.1016/j.ygyno.2022.04.012. PMID: 35550709Free PMC Article
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, Korach J, Huzarski T, Pignata S, Friedlander M, Baldoni A, Park-Simon TW, Tamura K, Sonke GS, Lisyanskaya A, Kim JH, Filho EA, Milenkova T, Lowe ES, Rowe P, Vergote I, Pujade-Lauraine E; SOLO2/ENGOT-Ov21 investigators
Lancet Oncol 2021 May;22(5):620-631. Epub 2021 Mar 18 doi: 10.1016/S1470-2045(21)00073-5. PMID: 33743851
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P
N Engl J Med 2018 Dec 27;379(26):2495-2505. Epub 2018 Oct 21 doi: 10.1056/NEJMoa1810858. PMID: 30345884
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P; SOLO2/ENGOT-Ov21 investigators
Lancet Oncol 2017 Sep;18(9):1274-1284. Epub 2017 Jul 25 doi: 10.1016/S1470-2045(17)30469-2. PMID: 28754483
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS
Lancet Oncol 2017 Jun;18(6):779-791. Epub 2017 Apr 21 doi: 10.1016/S1470-2045(17)30279-6. PMID: 28438473Free PMC Article

Diagnosis

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, Korach J, Huzarski T, Pignata S, Friedlander M, Baldoni A, Park-Simon TW, Tamura K, Sonke GS, Lisyanskaya A, Kim JH, Filho EA, Milenkova T, Lowe ES, Rowe P, Vergote I, Pujade-Lauraine E; SOLO2/ENGOT-Ov21 investigators
Lancet Oncol 2021 May;22(5):620-631. Epub 2021 Mar 18 doi: 10.1016/S1470-2045(21)00073-5. PMID: 33743851
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P
N Engl J Med 2018 Dec 27;379(26):2495-2505. Epub 2018 Oct 21 doi: 10.1056/NEJMoa1810858. PMID: 30345884
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P; SOLO2/ENGOT-Ov21 investigators
Lancet Oncol 2017 Sep;18(9):1274-1284. Epub 2017 Jul 25 doi: 10.1016/S1470-2045(17)30469-2. PMID: 28754483
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS
Lancet Oncol 2017 Jun;18(6):779-791. Epub 2017 Apr 21 doi: 10.1016/S1470-2045(17)30279-6. PMID: 28438473Free PMC Article
OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, Sovak MA, Yi J, Nycum LR
J Clin Oncol 2012 Jun 10;30(17):2039-45. Epub 2012 Apr 23 doi: 10.1200/JCO.2012.42.0505. PMID: 22529265Free PMC Article

Therapy

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, Korach J, Huzarski T, Pignata S, Friedlander M, Baldoni A, Park-Simon TW, Tamura K, Sonke GS, Lisyanskaya A, Kim JH, Filho EA, Milenkova T, Lowe ES, Rowe P, Vergote I, Pujade-Lauraine E; SOLO2/ENGOT-Ov21 investigators
Lancet Oncol 2021 May;22(5):620-631. Epub 2021 Mar 18 doi: 10.1016/S1470-2045(21)00073-5. PMID: 33743851
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P
N Engl J Med 2018 Dec 27;379(26):2495-2505. Epub 2018 Oct 21 doi: 10.1056/NEJMoa1810858. PMID: 30345884
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P; SOLO2/ENGOT-Ov21 investigators
Lancet Oncol 2017 Sep;18(9):1274-1284. Epub 2017 Jul 25 doi: 10.1016/S1470-2045(17)30469-2. PMID: 28754483
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS
Lancet Oncol 2017 Jun;18(6):779-791. Epub 2017 Apr 21 doi: 10.1016/S1470-2045(17)30279-6. PMID: 28438473Free PMC Article
OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, Sovak MA, Yi J, Nycum LR
J Clin Oncol 2012 Jun 10;30(17):2039-45. Epub 2012 Apr 23 doi: 10.1200/JCO.2012.42.0505. PMID: 22529265Free PMC Article

Prognosis

Ocular Toxicity of Mirvetuximab.
Corbelli E, Miserocchi E, Marchese A, Giuffrè C, Berchicci L, Sacconi R, Bandello F, Modorati GM
Cornea 2019 Feb;38(2):229-232. doi: 10.1097/ICO.0000000000001805. PMID: 30379722
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS
Lancet Oncol 2017 Jun;18(6):779-791. Epub 2017 Apr 21 doi: 10.1016/S1470-2045(17)30279-6. PMID: 28438473Free PMC Article
Management of Fallopian Tube Cancer.
Rai S, Maheshwari A
Rev Recent Clin Trials 2015;10(4):276-81. doi: 10.2174/1574887110666150923112556. PMID: 26411954
Primary fallopian tube cancer: domestic data and up-to-date review.
Horng HC, Teng SW, Huang BS, Sun HD, Yen MS, Wang PH, Tsui KH, Wen KC, Chen YJ, Chuang CM, Chao HT, Chang WH
Taiwan J Obstet Gynecol 2014 Sep;53(3):287-92. doi: 10.1016/j.tjog.2014.07.003. PMID: 25286779
Primary fallopian tube carcinoma.
Ajithkumar TV, Minimole AL, John MM, Ashokkumar OS
Obstet Gynecol Surv 2005 Apr;60(4):247-52. doi: 10.1097/01.ogx.0000158506.23663.79. PMID: 15795632

Clinical prediction guides

PRACTICAL MEANS OF PREOPERATIVE DIAGNOSTICS OF PRIMARY FALLOPIAN TUBE CANCER.
Sumtsov DH, Gladchuk IZ, Kashtalian NM, Sumtsov GO
Wiad Lek 2021;74(2):282-287. PMID: 33813487
Patterns and predictors of cancer-related fatigue in ovarian and endometrial cancers: 1-year longitudinal study.
Poort H, de Rooij BH, Uno H, Weng S, Ezendam NPM, van de Poll-Franse L, Wright AA
Cancer 2020 Aug 1;126(15):3526-3533. Epub 2020 May 21 doi: 10.1002/cncr.32927. PMID: 32436610
Serous ovarian, fallopian tube and primary peritoneal cancers: a common disease or separate entities - a systematic review.
Sørensen RD, Schnack TH, Karlsen MA, Høgdall CK
Gynecol Oncol 2015 Mar;136(3):571-81. Epub 2015 Jan 20 doi: 10.1016/j.ygyno.2015.01.534. PMID: 25615934
Treatment of fallopian tube cancer. Review of the literature.
Takeshima N, Hasumi K
Arch Gynecol Obstet 2000 Jul;264(1):13-9. doi: 10.1007/pl00007475. PMID: 10985612
Menstrual impact of contraception.
Stubblefield PG
Am J Obstet Gynecol 1994 May;170(5 Pt 2):1513-22. doi: 10.1016/s0002-9378(94)05013-1. PMID: 8178900

Recent systematic reviews

Weekly versus tri-weekly paclitaxel with carboplatin for first-line treatment in women with epithelial ovarian cancer.
Ngoi NY, Syn NL, Goh RM, Goh BC, Huang RY, Soon YY, James E, Cook A, Clamp A, Tan DS
Cochrane Database Syst Rev 2022 Feb 21;2(2):CD012007. doi: 10.1002/14651858.CD012007.pub2. PMID: 35188221Free PMC Article
Pathological findings following risk-reducing salpingo-oophorectomy in BRCA mutation carriers: A systematic review and meta-analysis.
Cheng A, Li L, Wu M, Lang J
Eur J Surg Oncol 2020 Jan;46(1):139-147. Epub 2019 Sep 5 doi: 10.1016/j.ejso.2019.09.002. PMID: 31521389
Serous ovarian, fallopian tube and primary peritoneal cancers: a common disease or separate entities - a systematic review.
Sørensen RD, Schnack TH, Karlsen MA, Høgdall CK
Gynecol Oncol 2015 Mar;136(3):571-81. Epub 2015 Jan 20 doi: 10.1016/j.ygyno.2015.01.534. PMID: 25615934
Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review.
Aravantinos G, Pectasides D
J Ovarian Res 2014;7:57. Epub 2014 May 19 doi: 10.1186/1757-2215-7-57. PMID: 24864163Free PMC Article
Laparoscopic staging for apparent early stage ovarian or fallopian tube cancer. First case series from a UK cancer centre and systematic literature review.
Brockbank EC, Harry V, Kolomainen D, Mukhopadhyay D, Sohaib A, Bridges JE, Nobbenhuis MA, Shepherd JH, Ind TE, Barton DP
Eur J Surg Oncol 2013 Aug;39(8):912-7. Epub 2013 May 27 doi: 10.1016/j.ejso.2013.05.007. PMID: 23721765

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Reviews

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...